Keyword: Dana-Farber Cancer Institute
Civetta Therapeutics is launching with $53 million from Deerfield to develop drugs targeting beta-propeller proteins with a first focus in cancer.
Grail has taken a few more steps forward in its quest to develop a diagnostic test capable of spotting cancer in its earliest stages.
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.
The Harvard researcher who first discovered the "exercise hormone" irisin reports it may be useful in bone formation.
Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.
Eli Lilly doubles down on its collaboration with the Dana-Farber Cancer Institute, extending the partnership for another three years.
Chief Scientific Officer Andrew Phillips was named CEO of C4 Therapeutics, a 2016 Fierce 15 winner.
The thoracic oncologist will head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
